Iparomlimab and Tuvonralimab (QL1706)Injection
Sponsors
Qilu Pharmaceutical Co., Ltd., Jiangsu Cancer Institute & Hospital
Conditions
Ovarian CancersResectable Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2
QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma
Not yet recruitingNCT06852456
Start: 2025-03-31End: 2034-12-31Target: 30Updated: 2025-02-28
Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer
Not yet recruitingNCT07407452
Start: 2026-02-01End: 2028-12-31Target: 50Updated: 2026-02-12